Replies to post #35977 on Revive Therapeutics Ltd (RVVTF)

[JoeBenson]

"There was no significant overall improvement trend between the Bucillamine and placebo arms for observed clinical symptoms and viral load data."

[tripmcneely]

And how does RVVTF monetize that?! They can’t short of a buyout. They do not have three years and millions of dollars to start fresh for a new study on said symptoms for a virus the majority of the world has moved on from. Hence BP buyout is their only out. And regardless of said symptom relief which comes with time regardless, propping their value up on the heels of a failed trial will not fetch a significant price